Posted by Michael Wonder on 03 Dec 2023
Agenda for the December 2023 PBAC intracycle meeting
1 December 2023 - The agenda for the December 2023 PBAC intracycle meeting is now available.
The PBAC will consider submissions for:
- Nivolumab (Opdivo) - multiple indications
- Ipilimumab (Yervoy) - multiple indications
- Patisiran (Onpattro) - amyloidosis
- Pembrolizumab (Keytruda) - multiple indications
- Upadacitinib monohydrate (Rinvoq) - rheumatoid arthritis
- Tyrosine kinase inhibitors (multiple) - non-small-cell lung cancer
- Tyrosine kinase inhibitors (multiple) - acute myeloid leukaemia
